Vertex Pharmaceuticals Incorporated
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vertex Pharmaceuticals Incorporated sits in the top decile of US sponsors by registered trial count (#156 of 15,742 sponsors by registered trial count).
Vertex Pharmaceuticals Incorporated: 191 sponsored US clinical trials, 20 recruiting.
Vertex Pharmaceuticals Incorporated sponsors 191 registered US clinical trials on ClinicalTrials.gov, 20 of them currently recruiting, and 144 completed. 67 of these trials are in Phase 3-4 (later-stage) and 119 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystic Fibrosis, with 20 trials.
Top-decile sponsor footprint
Vertex Pharmaceuticals Incorporated ranks in the top decile of sponsors by registered trial count (#156 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
144 of 161 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
191 total, page 2 of 4
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
NCT06176196
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
NCT05955872
A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment
NCT05865171
A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548
NCT05851157
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
NCT05867147
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
NCT05818852
Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment
NCT05704556
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
NCT05643495
A Phase 1, First-in-human Study of VX-668
NCT05727800
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
NCT05661734
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
NCT05660538
Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment
NCT05560464
A Phase 1, First-in-human Study of VX-634
NCT05579431
Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
NCT05558410
Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
NCT05553366
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin
NCT05541471
A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
NCT05518734
A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor
NCT05535959
Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
NCT05437120
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548
NCT05455502
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants
NCT05324410
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
NCT05153317
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
NCT05033080
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
NCT05034952
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
NCT04977336
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
NCT04923464
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
NCT04537793
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
NCT04474197
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
NCT04340362
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
NCT04235140
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older
NCT04183790
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
NCT04167345
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT04058366
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
NCT04058353
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
NCT04043806
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
NCT03912233
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
NCT03911713
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
NCT03764072
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
NCT03745287
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT03525574
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
NCT03691779
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
NCT03655678
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
NCT03601637
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03525548
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
NCT03633526
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
NCT03447262
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03525444
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03460990
A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation
NCT03537651
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 62 |
| Phase 2 | 57 |
| Phase 3 | 62 |
| Phase 4 | 5 |
What is open in the Vertex Pharmaceuticals Incorporated pipeline
20 recruiting of 191 indexed (10% open); 144 completed (75%).
Phase mix: 67 late (III/IV) vs 119 early (I/II) (early-phase heavy).
Top condition: Cystic Fibrosis (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vertex Pharmaceuticals Incorporated: open-pipeline peers nationwide
Peers matched on 191 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Vertex Pharmaceuticals Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 191 trials (± recruiting share)
- Vanderbilt-Ingram Cancer Center · 189 trials · 15% recruiting
- Hospital for Special Surgery, New York · 194 trials · 18% recruiting
- Nationwide Children's Hospital · 188 trials · 15% recruiting
- Arizona State University · 187 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Alexion Pharmaceuticals · 10% recruiting · 162 trials
- Zimmer Biomet · 10% recruiting · 115 trials
- University of Mississippi Medical Center · 10% recruiting · 96 trials
- Bastyr University · 11% recruiting · 19 trials
Related
What to do with this Vertex Pharmaceuticals Incorporated page
191 registered trials is a research-attention snapshot, not an endorsement of Vertex Pharmaceuticals Incorporated or any single study.
- 20 of Vertex Pharmaceuticals Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystic Fibrosis is the condition Vertex Pharmaceuticals Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystic Fibrosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vertex Pharmaceuticals Incorporated pipeline card: 191 registered trials from official public datasets.Report a data error.